90 related articles for article (PubMed ID: 7915576)
1. Evaluation of urinary pseudouridine as a tumor marker in lung cancer.
Lu JY; Lai RS; Liang LL; Wang HC; Lin TI
J Formos Med Assoc; 1994 Jan; 93(1):25-9. PubMed ID: 7915576
[TBL] [Abstract][Full Text] [Related]
2. Serum pseudouridine as a biochemical marker in small cell lung cancer.
Tamura S; Fujioka H; Nakano T; Hada T; Higashino K
Cancer Res; 1987 Nov; 47(22):6138-41. PubMed ID: 2822241
[TBL] [Abstract][Full Text] [Related]
3. Urinary pseudouridine as a tumor marker in patients with small cell lung cancer.
Tamura S; Fujii J; Nakano T; Hada T; Higashino K
Clin Chim Acta; 1986 Jan; 154(2):125-32. PubMed ID: 3006946
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of urinary and serum pseudouridine in diagnosis and monitoring of primary liver cancer.
Tu Z; Xu S; Wu M
Chin Med J (Engl); 1995 Mar; 108(3):204-8. PubMed ID: 7796629
[TBL] [Abstract][Full Text] [Related]
5. Urinary pseudouridine as a biochemical marker in the diagnosis and monitoring of primary hepatocellular carcinoma.
Tamura S; Fujioka H; Nakano T; Amuro Y; Hada T; Nakao N; Higashino K
Am J Gastroenterol; 1988 Aug; 83(8):841-5. PubMed ID: 2456010
[TBL] [Abstract][Full Text] [Related]
6. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
8. Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM
Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313
[TBL] [Abstract][Full Text] [Related]
9. Significant correlation between urinary N(1), N(12)-diacetylspermine and tumor invasiveness in patients with clinical stage IA non-small cell lung cancer.
Takahashi Y; Horio H; Sakaguchi K; Hiramatsu K; Kawakita M
BMC Cancer; 2015 Feb; 15():65. PubMed ID: 25884987
[TBL] [Abstract][Full Text] [Related]
10. [Muscle catabolism in patients with chronic obstructive pulmonary disease].
Montenegro Álvarez de Tejera P; Cabanes-Mariscal MA; Gutiérrez-Ortega C; Medina Font J; Villa-Corbatón MC; Gómez de Terreros J
Rev Clin Esp; 2011 Nov; 211(10):511-6. PubMed ID: 21993176
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of pseudouridine in patients with brain tumours.
Manjula S; Aroor AR; Raja A; Rao S; Rao A
Acta Oncol; 1993; 32(3):311-4. PubMed ID: 8323769
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
[TBL] [Abstract][Full Text] [Related]
13. Detection of elevated amounts of urinary pseudouridine in cancer patients by use of a monoclonal antibody.
Itoh K; Mizugaki M; Ishida N
Clin Chim Acta; 1989 May; 181(3):305-15. PubMed ID: 2758683
[TBL] [Abstract][Full Text] [Related]
14. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
[TBL] [Abstract][Full Text] [Related]
15. Urinary levels of pseudouridine in patients with psoriasis determined by high-performance liquid chromatography.
Nagayo K; Way BH
Arch Dermatol Res; 1982; 274(3-4):335-8. PubMed ID: 7165377
[TBL] [Abstract][Full Text] [Related]
16. Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer.
Scagliotti GV; Piani M; Gatti E; Gozzelino F; Albera C; Pozzi E
Eur Respir J; 1989 Sep; 2(8):746-50. PubMed ID: 2553476
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
18. Cut-off levels of NSE to differentiate SCLC from NSCLC.
Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
Yang J; Li R; Li A
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
[TBL] [Abstract][Full Text] [Related]
20. Urinary N1, N12-diacetylspermine is a non-invasive marker for the diagnosis and prognosis of non-small-cell lung cancer.
Takahashi Y; Sakaguchi K; Horio H; Hiramatsu K; Moriya S; Takahashi K; Kawakita M
Br J Cancer; 2015 Nov; 113(10):1493-501. PubMed ID: 26505680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
